Table 1 Demographic data of the study participants
|  | Chemotherapy group (n = 16) | Healthy controls (n = 14) | ||
|---|---|---|---|---|
Variable | Number | Percent | Number | Percent |
Age, years | ||||
 Mean (SD) | 67.0 (5.39) | N/A | 67.8 (5.24) | N/A |
 Range | 60–82 | N/A | 60–78 | N/A |
Race | ||||
 White | 11 | 68.8% | 14 | 100% |
 Black | 5 | 31.2% | 0 | 0.0% |
Ethnicity | ||||
 Hispanic or Latina | 2 | 12.5% | 2 | 14.3% |
 Non-Hispanic | 14 | 87.5% | 12 | 85.7% |
Education | ||||
 High school | 4 | 25.0% | 1 | 7.1% |
 Some college or junior college | 6 + 2 | 50.0% | 4 + 4 | 57.1% |
 College degree | 3 | 18.8% | 3 | 21.4% |
 Post college | 1 | 6.2% | 2 | 14.4% |
Stage | ||||
 I | 5 | 31.3% | N/A | N/A |
 II | 8 | 50.0% | N/A | N/A |
 III | 3 | 18.7% | N/A | N/A |
Regimen | ||||
 TC | 7 | 43.75% | N/A | N/A |
 TCPH | 1 | 6.25% | N/A | N/A |
 Paclitaxel/trastuzumab | 4 | 25.0% | N/A | N/A |
 Docetaxel/cyclophosphamide/PH | 1 | 6.25% | N/A | N/A |
 Carboplatin/paclitaxel | 1 | 6.25% | N/A | N/A |
 ddAC – paclitaxel | 1 | 6.25% | N/A | N/A |
 TAC | 1 | 6.25% | N/A | N/A |